What is needed for cpn now is a partner with deep pockets and fair bit of vision. Big pharma may have those pockets but not the vision. What they may want to do is to take cpn-10 'off the market' as an asset to use at a later date or deny another company from obtaining it. In that case, really a fraction of the price of what it is worth could be paid. Some wild cards are the fact that current biologics are no longer really interesting to big pharma, and that the unique science will somehow appeal to them in a way I do not understand. Whoever takes it has to go back into phase 2s.
Nadolol i'm much more excited about. I think the nadolol could now be sold on to ph3, or a bunch of ph2 for other diseases, like cystic fibrosis - and the inhaled versions allows for lots of future growth. I'm hopeful we will see some pharma fighting over these repurposed drugs for a number of lung ailments. To me its where Dr Glass's passion lies too, and I'd like him to stay in involved.
I'm hearing acquisition is now more probably than partnering. I really think with acquisition, that we are not going to see the full value of the company realised, and also I'm sad that this could indicate Dr G has had enough. I hope that is not the case.
re strategy - What happened? Did invion management really think they could flip over a lupus trial in 12 months, sell cpn10 at a profit to fund the respiratory franchise. I was taken in by that story, but it was a bit naive ,knowing now what I know about these drugs. Around 2 years too late with an mixed and partially unexplained trial outcome. Anyway, all water under the bridge now. We have to count our chickens...
I agree with others what we have now is a bargain and maintain a buy.
IVX Price at posting:
0.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)